| 455
HAFSTEINSDÓTTIR ET Al.
We report a retrospective population-based study performed to determine the total population incidence, clinical characteristics, and long-term prognosis of GBS patients in Iceland over a 20-year period, from 1995 to 2014.
| MATERIAL AND ME THODS

| Case definition and data collection
Our goal was to identify all patients diagnosed with GBS for the first time during the 20-year study period. Cases were identified by searching medical records from Landspitali University Hospital (LSH) and Akureyri Hospital (SAK) for all patients diagnosed with GBS during the study period. These are the two referral hospitals in the country, and are the only sites with access to a neurologist and an intensive care unit (ICU). We additionally searched the files from the neurophysiological laboratory at Landspitali University Hospital for potential cases. All residents of Iceland who were diagnosed with GBS during the study period and fulfilled the Brighton criteria for GBS were included. 16 Medical files were reviewed to determine gender, age at diagnosis, clinical presentation, laboratory values, and disease progression. Longterm follow up was determined by reviewing medical records from hospitals, healthcare centers, and private clinics around the country.
Disability was determined on admission, at the peak of the symptoms, six months after diagnosis, and at follow up using the GuillainBarré Syndrome Disability Scale (GBS disability scale). USA). The average annual incidence was estimated based on the mid-year population. 18 The Student's t-test was used to compare the means between two sets of independent samples, and confidence intervals were calculated assuming a Poisson distribution. The study period was divided into four 5-year blocks and a Pearson regression analysis was carried out to estimate the statistically significant difference in incidence between the blocks. Standardized mortality ratio (SMR) was calculated using life tables.
| Authorization
The study was approved by the Icelandic National Bioethics
Committee and Data Protection Authority.
| RE SULTS
| Patient characteristics
We identified 63 patients fulfilling the Brighton criteria for GBS during the study period. The average age at diagnosis was 46 years (median 47 years, range 1-89 years) and 32 were male. The Brighton criteria were fulfilled for level 1: 57% (36), level 2: 32% (20) 
| Incidence
The average annual incidence over the study period was 1.1 per 100 000 person years of observation. The number of cases was 10, 15, 23, and 17 when the study period was divided into four 5-year periods, with no statistically significant difference between them (P = 0.25-0.83). An increase in incidence was seen with increasing age (Table 1 ), and no difference in incidence was observed between the sexes. 
| Possible triggers
| Other diagnostic studies
Cerebrospinal fluid analysis was performed for 97% of cases (61/63), and elevated protein was found in 80% (50/61). The average time from symptom presentation to lumbar puncture was 9 days (median 7 days, range 1-37 days). CSF analysis was performed more than once for eight patients. One patient had normal protein levels 6 and 11 days after presentation and elevated levels after 29 days, and one patient had normal CSF protein levels both 2 and 44 days after presentation. The other six patients had elevated protein levels at first analysis. The results of the CSF analysis were missing for one, and the date of the procedure was unknown for two patients.
Guillain-Barré syndrome-associated autoantibodies were obtained for one patient and showed elevated IgM for anti-GD1 and anti-GM1. the disability scores at admission, nadir, 6 months after diagnosis, and last point of follow-up are summarized in Table 3 .
| Treatment and degree of disability
The average GBS disability score was 2.6 on admission, 3.5 at the nadir of the disease, 1.0 at 6 months and 0.9 at last follow-up.
Disability information was missing for one patient at diagnosis, one patient at nadir and two of the 59 patients that survived at 6 months.
Four deaths related to GBS (6%) were observed.
One year after diagnosis the SMR was 5.5 (confidence interval (CI) 2.5-12.3), and the SMR 3 years after diagnosis was 3.7 (CI 1.7-8.2).
| D ISCUSS I ON
We performed a population-based epidemiological study to determine the incidence and outcome of GBS in Iceland over a 20-year period. Iceland is an island, with a mean population of 297 645 during the study period, and contained two referral hospitals with ICUs Disability score (GBS DS): 0 = no symptoms; 1 = minor symptoms, able to run; 2 = able to walk more than 5 m without assistance but unable to run; 3 = able to walk 5 m with assistance; 4 = Chair bound or bedridden; 5 = requires ventilator assistance for at least part of the day; 6 = dead.
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that treat acute neurological patients. Recent reports of an association between GBS and the Zika virus gives the investigation of GBS frequency added importance. 15 Our incidence of 1.1/100 000 person years is comparable to or lower than several recently published studies from well-defined populations. 12 A study from Italy from 1995 to 1996 reported 120 cases with a population of 4.5 million and incidence of 1.4 per 100 000. 19 A study from the Western Balkans from 2009 to 2013 reported 327 cases, with a population of 9 million and of incidence 0.9 per 100 000. 9 A total population study from Taiwan from 1997 to 2011 reported 5998
cases with an incidence of 1.7 per 100 000. 20 A study from Finland from 2004 to 2013 reported 69 cases with a population of 380 000
and incidence of 1.8 per 100 000. 21 A recent study from Southern
Rogaland in Norway reports a considerably higher incidence of 2.3-3.2/100 000 in a well-defined population with similar size to ours. 4 They found 17 cases of GBS over a 2-year period using the National Institute for Neurological Disorders and Stroke (NINDS) diagnostic criteria and excluding children. We used the unambiguous and easily applicable Brighton Criteria for GBS diagnosis. We believe these are more specific than the NINDS criteria, but to our knowledge the two sets of diagnostic criteria have not been directly compared. The higher incidence seen in the Norwegian study may be partially explained by the use of different diagnostic criteria and the exclusion of children, which tend to have a lower incidence of GBS. We are not aware of any condition associated with GBS predisposition that is less prevalent in Iceland, and notably, the incidence of campylobacter infections during the study period was higher in Iceland than in Norway.
22,23
A recent population-based study from France reported a higher incidence of 2.4/100 000, based on the less specific International
Classifications of Disease-10 (ICD-10) code. This incidence was reduced to 1.2/100 000 when they (a) excluded all patients with another disease likely to be misclassified as GBS, (b) included only a single admission for GBS, (c) included only admissions longer than 5 days, and (d) received therapy with IVIG or plasmapheresis. 24 This lower incidence is almost identical to our findings.
The age specific incidence in this study tends to increase with increasing age (Table 1) , a trend that has also been described in previous studies.
12,20,24
The majority of our patients had the AIDP variant (87%) and 4%
had AMAN. None of our patients had acute motor and sensory axonal neuropathy (AMSAN). A similar pattern was described in recent studies from Finland and the Balkans, although the axonal form was somewhat more common. 9, 21 In a recent Norwegian study of 11 GBS patients, 91% (10) had AIDP and 9% (1) had AMSAN. 4 NCS were not performed on 16 patients, typically from the first 5 years of the study, when clinical neurophysiological testing was less accessible.
One patient in the current study had concurrent GBS and transverse myelitis. To our knowledge, only seven such cases have been reported previously.
25
A possible trigger was identified in 80% of the cases in this study, compared to 80% in the Finnish study, 68% in the Balkan study, and 54% in an Italian study. 9, 21, 26 The most commonly identified trigger was upper respiratory infection, as reported in the other three studies. Confirmatory diagnostic tests were very sporadically carried out however, and the specific infectious agent was identified for only a few cases. Four of our patients had undergone surgery and two had suffered head trauma, all <6 weeks prior to the onset of GBS. Surgery is increasingly identified as a possible GBS trigger. 21, 27 One (2%) of the individuals in our study had a relapsing disease, with two relapses 1 year apart. GBS recurrence has received little attention in the literature, but a population-based incidence study from Gothenburg found that 5%-6% of cases had recurrent GBS.
3 CIDP diagnosis must be considered when GBS appears to relapse.
Fourteen (22%) individuals in this study required mechanical ventilation during the illness, while other recent studies have reported a considerably lower incidence of mechanical ventilation, at 9%-13%. 9, 24, 28 We report that 6% (4) of patients died during admission or rehabilitation, deaths were directly related to GBS, and the causes of death were respiratory failure (3) and arrythmia (1) . Three out of the four patients died during the progressive phase, one after 5 months on respirator. The other two were geriatric patients with significant cardiovascular comorbidites, one had refused intubation and died on day 11, and the other died after 16 days on a respirator. The fourth patient died due to acute respiratory failure during rehabilitation on day 69, and an autopsy was not performed. Recently published studies of well-defined populations report similar or lower inpatient mortality, at 2.6%-5.8%. 7, 9, 19, 24 We report higher rates of both mechanical ventilation and death compared to previous studies, and the reasons for this are unclear.
Intensive Care Units (ICUs) are located at both hospitals and access to them is generally good. There is no evidence that lack of ventilatory support is the cause of death except for one individual that had refused intubation. Treatment delay is a possible factor, the average length from admission to start of treatment is 2 days in the current study but we do not have information from the other studies for comparison.
Long-term follow-up was available for the majority of our patients, with an average length of 6.5 years. Six months after diagnosis, 72% had no or only minor symptoms (GBS disability scale 0-1), 18%
could not walk unaided (GBS disability score 3-4), and none required ventilatory assistance. Two additional patients were able to walk without assistance at the last point of follow-up, and 13% required a walking aid. Improvement continued beyond 6 months, consistent with findings a recent meta-analysis reporting that 82% of patients were able to walk unaided after 6 months and 84% after 1 year. 29 Bersano et al reported a 3-5 year follow-up of 70 GBS patients from
Italy where 80% had no or minor symptoms (GBS disability scale 0-1) and 10% needed an aid to walk (GBS disability scale 3). 30 Forsberg et al did a follow-up study of 29 patients 10 years after diagnosis and found that 86% had minor or no symptoms and 10% were unable to walk unaided. 5 The outcomes reported in these studies are similar, indicating that the majority of GBS patients recover with minimal or no sequelae, but walking is impaired in 10%-15% of cases.
We believe our case finding is thorough and identifies all patients diagnosed with GBS in Iceland during the study period. We find a similar incidence to that reported in a recent study from France, but lower than other recent population-based studies, 4,24 which may be explained by the different diagnostic criteria used. The majority of our surviving patients made good recovery within 6 months, but 13% needed a walking aid at last follow up.
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